H.R. 8205 · 119th Congress · Health
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Reauthorizes through 2031 NIH and FDA programs supporting research on ALS and neurodegenerative disease treatments. AI-read
- IntroducedApr 6, 2026 Done
- CommitteeReported Jul 9, 2026 Done
- House floorPassed by voice vote · Jul 22, 2026 Done
- Senate floorPassed by voice vote · Sep 28, 2026 Done
- Chambers agreeIdentical, not needed Not needed
- PresidentSigned Nov 3, 2026 Done
What it does
This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The act reauthorizes
• grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
• grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
• a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.
Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
Congressional Research Service · summary of “Public Law” version · Nov 3, 2026
Who lobbies on it
No lobbying filing on file names H.R. 8205.
Organizations that named H.R. 8205 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
24 actions · newest first- Nov 3, 2026Became Public Law No: 119-138.
- Nov 3, 2026Signed by President.
- Oct 26, 2026Presented to President.
- Oct 14, 2026Message on Senate action sent to the House.
Show all 24 actionsShow fewer
- Sep 28, 2026Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
- Sep 28, 2026Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
- Jul 23, 2026Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
- Jul 22, 2026Motion to reconsider laid on the table Agreed to without objection.
- Jul 22, 2026On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026Considered as unfinished business. (consideration: CR H5159)
- Jul 20, 2026At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
- Jul 20, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
- Jul 20, 2026Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
- Jul 20, 2026Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- Jul 9, 2026Placed on the Union Calendar, Calendar No. 637.
- Jul 9, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
- May 21, 2026Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
- May 21, 2026Committee Consideration and Mark-up Session Held
- May 13, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
- May 13, 2026Subcommittee Consideration and Mark-up Session Held
- Apr 6, 2026Referred to the Subcommittee on Health.
- Apr 6, 2026Referred to the House Committee on Energy and Commerce.
- Apr 6, 2026Introduced in House
What members said about it
-
Rep. Calvert Applauds Senate Passage of the ACT for ALS Reauthorization Act
Today, Congressman Ken Calvert (CA-41) praised the Senate passage of the ACT for ALS Reauthorization Act, H.R. 8205.
“The passage of the ACT for ALS Reauthorization Act is a renewal of Congress’s commitment to finding cures and treatments for ALS.”
-
Rep. Calvert Praises Passage of the ACT for ALS Reauthorization Act
Today, Congressman Ken Calvert (CA-41) praised the unanimous passage of the ACT for ALS Reauthorization Act, H.R. 8205.
“As a Co-Chair of the bipartisan ALS Caucus, the effort to get the landmark ACT for ALS law across the finish line in 2021 was the result of the passion and determination of the ALS advocacy community.”